Literature DB >> 22460631

Toward the non-surgical management of locally advanced rectal cancer.

Alice Dewdney1, David Cunningham.   

Abstract

Neoadjuvant short-course radiotherapy and long-course chemoradiation (CRT) reduce local recurrence rates when compared to surgery alone and remain widely accepted as standard of care for patients with locally advanced rectal cancer. However, surgery is not without complications and a non-surgical approach in carefully selected patients warrants evaluation. A pathological complete response to CRT is associated with a significant improvement in survival and it has been suggested that a longer time interval between the completion of CRT and surgery increases tumor downstaging. Intensification of neoadjuvant treatment regimens to increase tumor downstaging has been evaluated in a number of clinical trials and more recently the introduction of neoadjuvant chemotherapy prior to CRT has demonstrated high rates of radiological tumor regression. Careful selection of patients using high-resolution MRI may allow a non-surgical approach in a subgroup of patients achieving a complete response to neoadjuvant therapies after an adequate time period. Clearly this needs prospective evaluation within a clinical trial setting, incorporating modern imaging techniques, and tissue biomarkers to allow accurate prediction and assessment of response.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22460631     DOI: 10.1007/s11912-012-0234-z

Source DB:  PubMed          Journal:  Curr Oncol Rep        ISSN: 1523-3790            Impact factor:   5.075


  77 in total

1.  Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer.

Authors:  E Kapiteijn; C A Marijnen; I D Nagtegaal; H Putter; W H Steup; T Wiggers; H J Rutten; L Pahlman; B Glimelius; J H van Krieken; J W Leer; C J van de Velde
Journal:  N Engl J Med       Date:  2001-08-30       Impact factor: 91.245

2.  Phase I/II study of preoperative cetuximab, capecitabine, and external beam radiotherapy in patients with rectal cancer.

Authors:  J-P Machiels; C Sempoux; P Scalliet; J-C Coche; Y Humblet; E Van Cutsem; J Kerger; J-L Canon; M Peeters; S Aydin; S Laurent; A Kartheuser; B Coster; S Roels; J-F Daisne; B Honhon; L Duck; C Kirkove; M-A Bonny; K Haustermans
Journal:  Ann Oncol       Date:  2007-01-05       Impact factor: 32.976

Review 3.  [Neoadjuvant treatment of rectal cancer: towards an individualised therapy].

Authors:  F Willeke; K Horisberger; S Post
Journal:  Z Gastroenterol       Date:  2006-10       Impact factor: 2.000

4.  Prognostic significance of tumor regression after preoperative chemoradiotherapy for rectal cancer.

Authors:  Claus Rödel; Peter Martus; Thomas Papadoupolos; Laszlo Füzesi; Martin Klimpfinger; Rainer Fietkau; Torsten Liersch; Werner Hohenberger; Rudolf Raab; Rolf Sauer; Christian Wittekind
Journal:  J Clin Oncol       Date:  2005-10-24       Impact factor: 44.544

5.  Should locally excised T1 rectal cancer receive adjuvant chemoradiation?

Authors:  J P Lamont; T M McCarty; R D Digan; R Jacobson; P Tulanon; W E Lichliter
Journal:  Am J Surg       Date:  2000-12       Impact factor: 2.565

6.  Extramural depth of tumor invasion at thin-section MR in patients with rectal cancer: results of the MERCURY study.

Authors: 
Journal:  Radiology       Date:  2007-02-28       Impact factor: 11.105

7.  Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203.

Authors:  Jean-Pierre Gérard; Thierry Conroy; Franck Bonnetain; Olivier Bouché; Olivier Chapet; Marie-Thérèse Closon-Dejardin; Michel Untereiner; Bernard Leduc; Eric Francois; Jean Maurel; Jean-François Seitz; Bruno Buecher; Rémy Mackiewicz; Michel Ducreux; Laurent Bedenne
Journal:  J Clin Oncol       Date:  2006-10-01       Impact factor: 44.544

8.  Preoperative versus postoperative chemoradiotherapy for locally advanced rectal cancer: results of the German CAO/ARO/AIO-94 randomized phase III trial after a median follow-up of 11 years.

Authors:  Rolf Sauer; Torsten Liersch; Susanne Merkel; Rainer Fietkau; Werner Hohenberger; Clemens Hess; Heinz Becker; Hans-Rudolf Raab; Marie-Therese Villanueva; Helmut Witzigmann; Christian Wittekind; Tim Beissbarth; Claus Rödel
Journal:  J Clin Oncol       Date:  2012-04-23       Impact factor: 44.544

9.  Sequential preoperative fluorodeoxyglucose-positron emission tomography assessment of response to preoperative chemoradiation: a means for determining longterm outcomes of rectal cancer.

Authors:  Jose G Guillem; Harvey G Moore; Timothy Akhurst; David S Klimstra; Leyo Ruo; Madhu Mazumdar; Bruce D Minsky; Leonard Saltz; W Douglas Wong; Steven Larson
Journal:  J Am Coll Surg       Date:  2004-07       Impact factor: 6.113

10.  Neoadjuvant capecitabine and oxaliplatin before chemoradiotherapy and total mesorectal excision in MRI-defined poor-risk rectal cancer: a phase 2 trial.

Authors:  Yu Jo Chua; Yolanda Barbachano; David Cunningham; Jacqui R Oates; Gina Brown; Andrew Wotherspoon; Diana Tait; Alison Massey; Niall C Tebbutt; Ian Chau
Journal:  Lancet Oncol       Date:  2010-01-25       Impact factor: 41.316

View more
  4 in total

1.  hcrcn81 promotes cell proliferation through Wnt signaling pathway in colorectal cancer.

Authors:  Yao Chen; Tingting Jiang; Lihong Shi; Kunyan He
Journal:  Med Oncol       Date:  2015-11-25       Impact factor: 3.064

2.  TAGLN suppresses proliferation and invasion, and induces apoptosis of colorectal carcinoma cells.

Authors:  Qinmin Li; Ruihua Shi; Yundong Wang; Xiaoping Niu
Journal:  Tumour Biol       Date:  2012-11-09

3.  Chances, risks and limitations of neoadjuvant therapy in surgical oncology.

Authors:  Florian Lordick; Ines Gockel
Journal:  Innov Surg Sci       Date:  2016-08-09

4.  The impact of driving time, distance, and socioeconomic factors on outcomes of patients with locally advanced rectal cancer.

Authors:  Joanna Gotfrit; Tharshika Thangarasa; Shaan Dudani; Rachel Goodwin; Patricia A Tang; Jose Monzon; Kristopher Dennis; Winson Y Cheung; Horia Marginean; Michael Vickers
Journal:  Public Health Pract (Oxf)       Date:  2020-05-24
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.